The biotechnology company has reported its candidate for treating amyotrophic lateral sclerosis patients has shown promising results in an early-phase study.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
The pharma firm has announced the agency has approved the company’s investigational new drug application for its Phase II trial of pemvidutide for obesity.
The pharma firm and collaborator Molecular Partners reported positive data out of their Phase II study for ensovibep, an antiviral for treating the virus.
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
The protease inhibitor PF-07321332 (co-administered with ritonavir) is designed for patients exposed to (or showing the first signs of) the COVID-19 virus.
The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization.
RedHill Biopharma has completed enrollment for its Phase II study exploring the use of opaganib in treating COVID-19 patients that have severe pneumonia.
Freenome’s multiomics platform is being used in a Phase II clinical trial to help identify patients most likely to respond to ADC Therapeutics’ antibody drug conjugate.
